The CMS BALANCE model offers states a path to expand coverage: states can opt into the model between May 2026 and January 2027, and CMS will negotiate lower drug pricing with manufacturers on behalf of participating states
Psychotomimetic, perceptual, cognitive, and neuroendocrine responses
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Are your weight loss medications FDA-approved
Our GLP-1 Daily Support supplement is designed to help provide the essential nutrients your body needs while on a calorie-reduced diet
Inhibitory effect of whey protein concentrate on SARS-CoV-2-targeted furin activity and spike protein-ACE2 binding in methotrexate-induced lung damage